UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
21.35
+0.83 (4.04%)
Feb 6, 2026, 4:00 PM EST - Market closed
UroGen Pharma Stock Forecast
Stock Price Forecast
The 8 analysts that cover UroGen Pharma stock have a consensus rating of "Strong Buy" and an average price target of $29.5, which forecasts a 38.17% increase in the stock price over the next year. The lowest target is $3.00 and the highest is $47.
Price Target: $29.5 (+38.17%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for UroGen Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $33 | Strong Buy | Maintains | $33 | +54.57% | Jan 23, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $33 | Strong Buy | Maintains | $33 | +54.57% | Jan 5, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +87.35% | Oct 27, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +17.10% | Oct 27, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +17.10% | Oct 3, 2025 |
Financial Forecast
Revenue This Year
114.33M
from 90.40M
Increased by 26.47%
Revenue Next Year
240.84M
from 114.33M
Increased by 110.65%
EPS This Year
-3.24
from -2.96
EPS Next Year
-1.20
from -3.24
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 125.7M | 298.2M | ||||
| Avg | 114.3M | 240.8M | ||||
| Low | 102.7M | 187.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 39.1% | 160.8% | ||||
| Avg | 26.5% | 110.7% | ||||
| Low | 13.6% | 63.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -3.13 | -0.57 | ||||
| Avg | -3.24 | -1.20 | ||||
| Low | -3.33 | -1.67 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.